Answers are grounded in this paper and cite their sources.
Malaria, caused by the protozoan Plasmodium, is a devastating disease with over 200 million new cases reported globally every year. Although immunization is arguably the best strategy to eliminate malaria, despite decades of research in this area we do not have an effective, clinically approved antimalarial vaccine. The current impetus in the field is to develop vaccines directed at the pre-erythrocytic developmental stages of Plasmodium, utilizing novel vaccination platforms. We here review the most promising pre-erythrocytic stage antimalarial vaccine candidates.
No takes yet. Share an insight, caveat, or question.
Marques-da-Silva et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: